Literature DB >> 29325860

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

Erica L Gornstein1, Sara Sandefur2, Jon H Chung3, Laurie M Gay3, Oliver Holmes3, Rachel L Erlich3, Salil Soman4, L Katherine Martin2, Andrea V Rose2, Philip J Stephens3, Jeffrey S Ross3, Vincent A Miller3, Siraj M Ali3, Sibel Blau2.   

Abstract

Entities:  

Keywords:  BRCA reversion; Circulating tumor DNA; Metastatic breast cancer; PARP inhibitor; ctDNA

Mesh：

Substances：

Year:  2017        PMID： 29325860     DOI： 10.1016/j.clbc.2017.12.010

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN： 1526-8209            Impact factor:   3.225


× No keyword cloud information.
  14 in total

Review 1.  PARP inhibitor resistance: the underlying mechanisms and clinical implications.

Authors:  He Li; Zhao-Yi Liu; Nayiyuan Wu; Yong-Chang Chen; Quan Cheng; Jing Wang
Journal:  Mol Cancer       Date:  2020-06-20       Impact factor: 27.401

Review 2.  DNA Damage: From Threat to Treatment.

Authors:  Antonio Carusillo; Claudio Mussolino
Journal:  Cells       Date:  2020-07-10       Impact factor: 6.600

3.  Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR.

Authors:  Saira Khalique; Stephen J Pettitt; Ger Kelly; Nina Tunariu; Rachael Natrajan; Susana Banerjee; Christopher J Lord
Journal:  J Pathol Clin Res       Date:  2019-11-20

Review 4.  PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.

Authors:  Elizabeth K Lee; Ursula A Matulonis
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

5.  Prognostic value of ubiquitin E2 UBE2W and its correlation with tumor-infiltrating immune cells in breast cancer.

Authors:  Yan Yuan; Wei-Wei Xiao; Wei-Hao Xie; Rong-Zhen Li; Yuan-Hong Gao
Journal:  BMC Cancer       Date:  2021-04-30       Impact factor: 4.430

6.  Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients.

Authors:  Duna H Barakeh; Rasha Aljelaify; Yara Bashawri; Amal Almutairi; Fatimah Alqubaishi; Mohammed Alnamnakani; Latifa Almubarak; Abdulrahman Al Naeem; Fatema Almushawah; May Alrashed; Malak Abedalthagafi
Journal:  Oncotarget       Date:  2021-03-30

7.  Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation.

Authors:  Lee S Schwartzberg; Lesli A Kiedrowski
Journal:  Ther Adv Med Oncol       Date:  2021-04-05       Impact factor: 8.168

8.  Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.

Authors:  Stephen J Pettitt; Jessica R Frankum; Marco Punta; Stefano Lise; John Alexander; Yi Chen; Timothy A Yap; Syed Haider; Andrew N J Tutt; Christopher J Lord
Journal:  Cancer Discov       Date:  2020-07-22       Impact factor: 38.272

Review 9.  New Insights into Therapy-Induced Progression of Cancer.

Authors:  Polina V Shnaider; Olga M Ivanova; Irina K Malyants; Ksenia S Anufrieva; Ilya A Semenov; Marat S Pavlyukov; Maria A Lagarkova; Vadim M Govorun; Victoria O Shender
Journal:  Int J Mol Sci       Date:  2020-10-23       Impact factor: 5.923

10.  Longitudinal and multi-tissue molecular diagnostics track somatic BRCA2 reversion mutations that correct the open reading frame of germline alteration upon clinical relapse.

Authors:  Shelly Sorrells; Kelly E McKinnon; Ashleigh McBratney; Christopher Sumey
Journal:  NPJ Genom Med       Date:  2021-02-22       Impact factor: 8.617
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.